Hasegawa H, Imada A, Horiuchi A, Nishii Y, Fukushima M, Kurokawa E
J Antimicrob Chemother. 1984 Sep;14 Suppl B:135-42. doi: 10.1093/jac/14.suppl_b.135.
The pharmacokinetics of cefotaxime were studied in 13 patients on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD). One gram of cefotaxime was administered intravenously or intraperitoneally. In the haemodialysis patients, the serum concentration after 4h was 9.4 mg/l and the T1/2 was 1.31 h. The 6-h value and T1/2 in the CAPD (intravenous) patients were 4.5 mg/l and 1.59 hours, while the peak value in the dialysate was 11.6 mg/l. In the CAPD (intraperitoneal) patients, the cefotaxime concentration in the dialysate was 157 mg/l after 6 h and the peak value in the serum was 9.1 mg/l. Since cefotaxime is easily removed from the blood by both the haemodialysis and CAPD methods, accumulation of the drug in patients undergoing dialysis is unlikely to occur.
对13名接受血液透析或持续性非卧床腹膜透析（CAPD）的患者进行了头孢噻肟的药代动力学研究。静脉注射或腹腔注射1克头孢噻肟。在血液透析患者中，4小时后的血清浓度为9.4毫克/升，半衰期为1.31小时。CAPD（静脉注射）患者的6小时值和半衰期分别为4.5毫克/升和1.59小时，而透析液中的峰值为11.6毫克/升。在CAPD（腹腔注射）患者中，6小时后透析液中的头孢噻肟浓度为157毫克/升，血清中的峰值为9.1毫克/升。由于血液透析和CAPD方法都能轻易地从血液中清除头孢噻肟，因此透析患者不太可能出现药物蓄积的情况。
